Photo Release -- Samaritan Recognized for HIV Innovation
Frost & Sullivan's 'North American Technology Innovation Award' Goes
to Samaritan's SP-01A, a Unique HIV Entry Inhibitor
LAS VEGAS, Nov. 16, 2006 (PRIMEZONE) -- Samaritan Pharmaceuticals
Inc. and Samaritan PharmaPlaz Ireland, Inc. (AMEX:LIV) a developer of
innovative drugs, announced today it has been selected by the
prestigious Frost & Sullivan Best Practices Group to receive the 2006
North American Technology Innovation Award, for its HIV Entry
Inhibitor Drug Candidate SP-01A targeting HIV drug resistance.
A photo accompanying this release is available at
"This award is a testament to the dedication of our scientists at
Samaritan Labs, Georgetown University, our in-house drug development
team, PharmaPlaz, Ireland, Samaritan's collaborative manufacturing
partner and last but not least, our administrative team," stated Dr.
Janet Greeson, CEO of Samaritan. "I'd like to thank everyone for the
vital roles they've played in making it possible for Samaritan to be
honored with this award."
According to Frost & Sullivan:
"The Frost & Sullivan 2006 Technology Innovation Award in the field
of HIV drug development goes to Samaritan Pharmaceuticals, Inc. in
recognition of the company's effort in developing the antiviral
therapy based drug, SP01A. Notably, this therapeutic treatment offers
respite as a drug that does not develop resistance along with
ensuring safety and tolerance levels while delivering the required
Excerpts from Award:
-- "This drug would come across as one that eliminates side effects
and noncompliance issues, and, hence, has a cutting edge over the
other antiretroviral therapies."
-- "This seems a better mode of prevention as it stops the HIV virus
from invading healthy cells rather than attacking the virus, when
it has already established itself in the cell."
"In summary, the Frost & Sullivan 2006 Technology Innovation Award
recognizes Samaritan Pharmaceuticals, Inc. for its development of a
novel-therapy solution targeting HIV. This solution incorporates a
unique entry-level inhibitor that does not confer resistance or
cross-resistance while ensuring patient safety and exhibiting high
potent inhibition toward HIV."
To read full Frost & Sullivan award commentary, go to
About Frost & Sullivan:
Frost & Sullivan serves an extensive clientele that includes Global
1000 companies, emerging companies, and the investment community by
providing comprehensive industry coverage that reflects a unique
global perspective and combines ongoing analysis of markets,
technologies, econometrics, and demographics. For more information,
Samaritan Pharmaceuticals: "We LIV....to Save Lives."
Samaritan is a small-cap Biotech, driven to discover, develop and
commercialize innovative therapeutics for AIDS, Alzheimer's, Cancer
and Heart disease patients. Look at www.samaritanpharma.com. Please
register on Website so we can notify you of upcoming conference
calls, news and events.
The Samaritan Pharmaceuticals Inc. logo is available at
The company disclaims any information that is created by an outside
party and endorses only information that is communicated by its press
releases, filings and Website. This news release contains
forward-looking statements that reflect management's current beliefs
about the potential for its drug candidates, science and technology.
However, as with any biopharmaceutical under development, there are
significant risks and uncertainties in the process of development and
regulatory review. There are no guarantees that products will prove
to be commercially successful. For additional information about the
factors that affect the company's business, please read the company's
latest Form 10-K/A filed November 2, 2006. The company undertakes no
duty to update forward-looking statements.
The photo is also available at NewsCom, (www.newscom.com), and via AP
CONTACT: Samaritan Pharmaceuticals, Inc.